anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Intracerebral hemorrhage (ICH) is a major cause of death and disability worldwide. The benefits of electrical stimulation in the treatment of respiratory dysfunction in patients on mechanical ventilation is unknown. Nevertheless, there is a dearth of evidence-based medical research concerning its clinical efficacy. From January 2019 to January 2023, every enrolled patients experienced respiratory dysfunction after ICH while being supported by mechanical ventilation. A total of 205 eligible patients were enrolled and then allocated into 2 groups: control group and observation group. 133 patients was selected and administered standard treatment as control group. Based on conventional treatment, other 72 patients were administered diaphragm electrical stimulation (DES) treatment. We examined information from current medical records, encompassing all initial data and predictive follow-up data, such as the weaning success rate, occurrence of ventilator-associated pneumonia (VAP), duration of stay in the intensive care unit (ICU) and hospital, expenses related to hospitalization, and mortality within 30 days. The baseline clinical data of the 2 groups did not exhibit any statistically significant disparities (all P > .05). The rate of successful weaning showed a significant increase in the DES group when compared to the control group (P = .025). In patients with respiratory dysfunction due to ICH, treatment with DES resulted in a significant reduction in the duration of invasive ventilation (9.8 ± 2.1 vs 11.2 ± 2.6, P < .01) and total ventilation time (9.8 ± 2.1 vs 11.2 ± 2.6, P < .01). It also led to a decrease in the length of stay in the ICU (15.67 ± 3.76 vs 17.53 ± 4.28, P = .002) and hospitalization cost (11500 vs 13600, P = .001). Additionally, DES treatment resulted in a lower incidence of VAP (73.61% vs 86.46%, P = .022) and improved 30-day mortality (P < .05), without any significant adverse effects. The findings of this research indicate that DESs have a positive impact on enhancing the rate of successful weaning and reducing the incidence of VAP. It decreases the duration of invasive ventilation and total ventilation time while also improving the mortality rate within 30 days. This therapy could offer a fresh alternative for respiratory impairment in patients undergoing mechanical ventilation.
A method of reducing inflamation in a variety of disorders by using an intraperitoneal solution of magnesium. The solution can be used for treating inflammatory and inflammation-related disorders in animals and/or humans. Application of the solution reduces inflammation and thereby assists in the healing process. An alternative method involves the intraperitoneal administration of a solution containing magnesium salts. Another alternative method provides for treatment of inflammatory and inflammation-related disorders in animals by way of intraperitoneal administration of a solution containing magnesium salts, methenamine or its salts and dextrose. The method further provides the use of methenamine or its salts and/or dextrose in combination with magnesium.
FIELD: medicine. SUBSTANCE: method involves carrying out indirect electrochemical blood oxidation with sodium hypochlorite solution for performing plasmapheresis. The 0.06% sodium hypochlorite solution is intravenously dripped in the amount of 1/10 of circulating blood volume during 60 min. Plasmapheresis is carried out during 40- 50 min. Blood exfusion is 1000.0 ml, flow rate is 40-50 ml/min. The whole treatment course is 3-6 sessions long in everyday mode. EFFECT: enhanced effectiveness of treatment; intensive removal of endotoxins. 1 dwg
Participants will receive 50, 75, 100 or 150 mg eq. (\[paliperidone palmitate\] mg equivalent \[to paliperidone\]) long acting formulation of paliperidone palmitate once monthly (PP1M) intramuscular injection for 4 months (17 weeks) plus option to continue 3 more months if not stabilized depending on the participant's clinical safety, tolerability and efficacy requirements.
NEW MATERIAL:The compound of formulaI(R1 is H or CH3; R2 is 2-3C alkylene; n is 2-9; two carboxyl groups of the benzene ring may form an acid anhydride bond) and its acid anhydride. EXAMPLE:Anhydride of 4-methacryloxypolyethylene glycol (n=2) trimellitate. USE:A component of various adhesive compositions. An adhesive composition can be prepared by combining the compound with one or more polymerizable compounds having ethylenic unsaturated bond and a polymerization initiator, and the composition is curable at normal temperature or relatively low temperature or with heat, and has high adhesivity especially to metals and tooth, etc., high rate of cure, and excellent flexibility and solvent resistance. PROCESS:The acid anhydride of formulaIcan be prepared by reacting the compound of formula II with trimellitic anhydride or its reactive derivative in a solvent. The product can be converted to the ester compound of formulaIby a conventional hydrolysis.
For research on HIV/AIDS, it is important to elucidate the complex viral-host interaction, host dependency factors (HDFs), and restriction factors. However, the regulatory network of HIV-resistance-related factors remains not well understood. Therefore, we integrated four publicly available HIV-related transcriptome datasets, along with three datasets on HIV-infection-related DNA methylation, miRNA, and ChIP-seq, to predict the factors influencing HIV resistance and infection. Our approach involved differential analysis, functional annotation, and protein-protein interaction network analysis. Through comprehensive analyses, we identified 25 potential HIV-resistance-related genes (including shared EGF) and 24 HIV-infection-related hub genes (including shared JUN). Additionally, we pinpointed five key differentially methylated genes, five crucial differentially expressed microRNAs, and five significant pathways associated with HIV resistance. We mapped the potential regulatory pathways involving these HIV-resistance-related factors. Among the predicted factors, RHOA, RAD51, GATA1, IRF4, and CXCL8 have been validated as HDFs or restriction factors. The identified factors, such as JUN, EGF, and PLEK, are potential HDFs or restriction factors. This study uncovers the gene signatures and regulatory networks associated with HIV-1 resistance, suggesting potential targets for the development of new therapies against HIV/AIDS.
BACKGROUND: Previous studies have demonstrated that trans fatty acids (TFAs) intake was linked to an increased risk of chronic diseases. As a novel systemic inflammatory biomarker, the clinical value and efficacy of the systemic immune-inflammation index (SII) have been widely explored. However, the association between TFAs and SII is still unclear. Therefore, the study aims to investigate the connection between TFAs and SII in US adults.
METHODS: The study retrieved data from the National Health and Nutrition Examination Survey (NHANES) for the years 1999-2000 and 2009-2010. Following the exclusion of ineligible participants, the study encompassed a total of 3047 individuals. The research employed a multivariate linear regression model to investigate the connection between circulating TFAs and SII. Furthermore, the restricted cubic spline (RCS) model was utilized to evaluate the potential nonlinear association. Subgroup analysis was also conducted to investigate the latent interactive factors.
RESULTS: In this investigation, participants exhibited a mean age of 47.40 years, with 53.91% of them being female. Utilizing a multivariate linear regression model, the independent positive associations between the log2-transformed palmitelaidic acid, the log2 transformed-vaccenic acid, the log2-transformed elaidic acid, the log2-transformed linolelaidic acid, and the log2-transformed-total sum of TFAs with the SII (all P < 0.05) were noted. In the RCS analysis, no nonlinear relationship was observed between the log2-transformed palmitelaidic acid, the log2 transformed-vaccenic acid, the log2-transformed elaidic acid, the log2-transformed linolelaidic acid, the log2-transformed-total sum of TFAs and the SII (all P for nonlinear > 0.05). For the stratified analysis, the relationship between the circulating TFAs and the SII differed by the obesity status and the smoking status.
CONCLUSIONS: A positive association was investigated between three types of TFA, the sum of TFAs, and the SII in the US population. Additional rigorously designed studies are needed to verify the results and explore the potential mechanism.
The present invention relates to the pharmaceutical compositions for treatment of skin diseases and affections and of the exposed tissue of a human, including malignant skin tumors. The compositions are applied to the affected skin or tissues and consist of an effective dosage amount comprising antiseptic non-steroid remedy (f. ex. diclofenac, indomethacine, naproxen and others) and an effective dosage amount of non-toxic hyaluronic acid and/or salts thereof, and /or homologues, analogues, derivatives, esters, fragments and /or sub-units of hyaluronic acid. The hyaluronic acid transports, accumulates and deposits the remedy into the affected tissues and acts as an independent system. The compositions are presented in a form convenient for percutaneous transport into the skin (f. ex. gel or cream) and are dosed (f.ex. tube).
Participant in this group will undergo SNAG technique on lumbar vertebra with active spinal movement according to Mulligan, (2004). Participants will be in a sitting position on the edge of the couch while both feet will be on a footrest. A stabilization belt will be used around the patient's waist and the therapist's hips and the researcher standing behind the patient well supported with stabilization belt. The researcher places one thumb or hypothenar eminence (pisiform bone) reinforced by the other on the spinous process of the implicated lumbar vertebra and then apply pressure posterior-anteriorly on the spinous process, the pressure will be sustained and the patient concurrently performs active spinal movement. SNAGS will be applied with 3 repetitions on the first day and 10 repetitions from next visit. SNAG will be used twice a week for 6 weeks.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to cardiology, hematology, and can be applied for reduction of spontaneous erythrocyte aggregation in case of arterial hypertension with metabolic syndrome. For this purpose administered are dosed static and dynamic physical activity, daily swimming for not less than 40 min. per day in the middle of the day, as well as lisinopril in dose 10 mg 1 time per day in the morning and methformin 500 mg 2 times per day. Physical activity includes morning hygienic gymnastics, therapeutic-preventive gymnastics and divided physical exercises during the day. Treatment course is 2 months. ^ EFFECT: combination of treatment methods makes it possible to reduce spontaneous erythrocyte aggregation, which assists prevention of thrombotic complications in said category of patients. ^ 2 ex
FIELD: medicine; pharmaceuticals.SUBSTANCE: method is proposed to produce total RNA and zymosan polysaccharide from yeast cells Saccharomyces cerevisiae, strain of VKPM Y-448 and therapeutic agent based thereon. Method is characterized by that it involves destruction of yeast cells in buffer with pH 7.4, containing 10 mM Tris, 20 mM EDTA and 0.5 M NaCl, treatment with sodium dodecylsulphate (SDS) in concentration of 1.0 % at 20–30 °C for 20–50 min and chloroform in concentration of up to 25 % for 20–30 minutes at 20–30 °C. Obtained mixture is centrifuged for 20 minutes, followed by separation of the supernatant containing the aqueous extract of total RNA from the residue—a clot of proteins and polysaccharides containing zymosan, washed from the bulk of the lipids. SDS solution is added to the obtained aqueous cell extract containing total RNA to a final concentration of 2 % and held for 60–90 minutes at 0 °C until precipitation of the SDS complex with denatured proteins, which is removed by centrifugation at 8000 g, 20 min, 0 °C, and total RNA is obtained by deposition from supernatant liquid lithium chloride solution with salt concentration of 3.5 M with removal of main pool of impurity proteins together with remaining solution during washing. Obtained residue is washed twice with 3.5 M lithium chloride salt solution and dissolved in water. Solution is clarified by centrifugation at 8000 g, 20 min, 4 °C and passed through a filter with pore diameter of 0.22 mcm, after which RNA is precipitated by adding ethanol to concentration of 50–55 %, and the formed precipitate is separated by centrifugation at 8000 g, 20 min, 4 °C, washed with 60 % ethanol and dissolved in isotonic solution with output of total RNA preparation 200–240 mg of 100 g of yeast biomass. Produced protein-polysaccharide clot containing zymosan is suspended in 1 % sodium dodecyl sulphate solution, suspension is stirred at 50–60 °C for 20–30 minutes and zymozan polysaccharide is separated from protein solution by centrifugation at 8000 g, 15 min, 20 °C. Obtained precipitate is washed, the purified zymosan polysaccharide is dried at a temperature of +40–45 °C for one day and transferred into a fine powder state. What is also presented is an antiviral and antibacterial agent containing total RNA and zymosan polysaccharide obtained by the above method and having ratio of 1:2.5 to 1:10, as well as solvent or ointment base with target additives at the following quantitative content of components, wt %: total RNA—0.2–3.0, zymosan polysaccharide—0.5–30.0, solvent or ointment base with target additives—balance up to 100 %.EFFECT: invention enables to obtain total RNA and zymosan polysaccharide in one technological process, as well as obtaining an agent exhibiting high interferon-inducing and phagocytosis-stimulating activities.4 cl, 2 dwg, 4 tbl, 8 ex
OBJECTIVE: Recent studies suggest that adult cardiac surgery performed in the morning increases the risk of major adverse cardiac events, but it is unclear whether this association exists in pediatric cardiac surgery. This study aimed to determine whether the composite outcome of in-hospital mortality and low cardiac output syndrome (LCOS) differs between morning and afternoon pediatric cardiac surgeries.
METHODS: This retrospective cohort study enrolled 23,433 consecutive pediatric patients who underwent cardiac surgery between August 2014 and December 2021. Pediatric patients who had surgery start time between 8 AM and 11 AM (morning surgery) versus between 2 PM and 5 PM (afternoon surgery) were compared in the risk of the composite outcome. The Society of Thoracic Surgeons-European Association for Cardiothoracic Surgery (STAT) score was used to indicate the surgical complexity. The adjusted odds radio (aOR) for the composite outcome was calculated using multivariate logistic regression. The restricted cubic spline (RCS) was performed to characterize the continuous relationship between the surgery start time and risk of the composite outcome.
RESULTS: Of 16,534 included pediatric patients, 1.2% died after morning surgery and 0.6% died after afternoon surgery. The composite outcome of in-hospital mortality and LCOS occurred in 14.2% (1,507 of 10,591) of morning surgeries and 8.6% (514 of 5,943) of afternoon surgeries: morning versus afternoon aOR, 1.186 (95% CI, 1.046 to 1.344; p = 0.008). The association was also determined in children aged 3 to 18 years (aOR = 1.598, p = 0.003), weighted between 6.1 to 8.7 kg (aOR = 1.453, p = 0.006), or more than 13 kg (aOR = 1.488, p = 0.019), and with STAT category 4-5 (aOR = 1.367, p = 0.014) subgroups. The RCS plot showed that the aOR of the composite outcome decreased with a delay in the start time of surgery.
CONCLUSION: Our study supports the selective afternoon scheduling of specific pediatric cardiac surgeries, but further investigation is needed in a multicenter cohort.KEY MESSAGESThis study reviewed 23,433 consecutive pediatric patients who underwent cardiac surgery between August 2014 and December 2021.This study suggested that afternoon surgery was associated with a lower risk of the composite outcomes of in-hospital mortality and low cardiac output syndrome.The above association was also determined in children aged 3 to 18 years, weighted between 6.1 and 8.7 kg, or more than 13 kg, and with STAT category 4-5 subgroups.The restricted cubic spline plot showed that the adjusted risk of the composite outcome decreased with a delay in the start time of surgery.Our findings support selective afternoon scheduling for specific pediatric cardiac surgery.
The purpose of this research program is to use Dartfish technology and Functional Movement Screen to assess female athletes pre- and post injury prevention program.The study will include ninety-four females: forty-seven who complete a nine week program focusing on neuromuscular and proprioceptive exercises to improve landing techniques, and forty-seven who go about their normal preseason training regimen. This program has no more risk than if each athlete were to work out at their own gym. Each athlete will be given two questionnaires before and after completing the program in order to determine their level of activity has changed as well as uncover any underlying knee issues. Participants will also go through a series of functional and movement tests to reveal any imbalances, and determine whether or not they have improved by going through the prevention program.

All functional and movement tests will be video recorded. These recordings will only be used for the purpose of conducting this research study and will only be viewed by the HFHS investigators participating in the study. We will follow-up with each athlete one year later to see if there are any lasting effects from the program and re-test each athlete at that time to validate any results
Lung transplant recipients (LTR) experience more transplant-related complications, higher health resource utilization, and higher mortality than recipients of other solid organs. Prevention and detection of early complications is known to reduce the likelihood of future impairments in lung function and, therefore, morbidity and mortality. Despite the scarce donor organs and financial resources expended to support individuals throughout the lung transplant experience, no randomized controlled trials (RCT) have tested interventions designed to promote self-care behaviors with the aim of improving transplant-related health after lung transplant. The purpose of this RCT is to compare the efficacy of a novel behavioral intervention, Pocket PATH (Personal Assistant for Tracking Health) for promoting self-care and improving health outcomes relative to standard care after lung transplantation. Pocket PATH provides LTR a hand-held device with customized data recording, trending, and decision-support programs to promote their self-care behaviors. Based on the promising results from our early trials, a full-scale RCT has been designed to rigorously test the efficacy of Pocket PATH in promoting self-care agency, self-care behaviors, and hence improving transplant-related health. A sample of 214 LTR who survive the immediate intensive care unit recovery period will be randomly assigned to either the intervention group, who will be instructed to use the Pocket Path device and its programs designed for self-monitoring, adhering to the regimen, and communicating condition changes to the transplant team, or the control group who will receive standard instructions regarding the post-transplant regimen (including health monitoring). Information will be collected from participants at baseline and 1 week, 2, 6, and 12 months after discharge from the hospital following lung transplantation. Longitudinal, repeated-measures models with planned comparisons will be used to test the hypotheses for the primary aims. It is hypothesized that subjects in the Pocket PATH group will develop higher levels of self-care agency and perform self-care behaviors more often than subjects in the control group and, therefore, will experience fewer transplant-related complications, re-hospitalizations, and better health related quality of life.
Autism spectrum disorder (ASD) is a very common developmental condition, yet the cause remains unknown and effective treatment options to improve outcomes remain limited. Most autistic adults experience significant motor function difficulties involving balance, posture, coordination, and strength that negatively affect their quality of life, social interaction, confidence and daily functioning. Therefore, such difficulties remain an important treatment target. However, there are no known effective clinical interventions for such difficulties. Investigators previously showed that the part of the brain that controls motor movements, i.e. motor cortex, showed hyperplasticity, as assessed by theta-burst magnetic brain stimulation (TBS), in autistic adults. Hyperplasticity may adversely affect brain health and behavior. Investigators also previously found that rTMS may reduce such hyperplasticity in the motor cortex in autistic adults.

In this project, 100 autistic adults with significant motor function difficulties and 50 neurotypical (NT) controls matched 2:1 based on age, sex, and IQ will be recruited. At the Centre for Addiction and Mental Health, Toronto, each autistic adult's participation will consist of nine visits, while each NT adult's participation will include two visits.

All participants, both autistic and NT, will undergo clinical, adaptive, and motor function assessments during their first visit (lasting approximately 3 hours) and a pre- and post-intermittent-TBS (iTBS) session with electroencephalography (EEG) to induce and assess plasticity in the left or right motor cortex (depending on handedness) during their second visit (lasting approximately 2.5 hours). Based on the preliminary evidence that rTMS reduces hyperplasticity in the motor cortex in autistic adults, the investigators will then use a randomized, double-blind, sham-controlled design for bilateral 5-session rTMS on the motor cortex. Autistic participants will be randomized (1:1, sex-stratified) to receive either active or sham rTMS (120 trains of 50 pulses with an inter-train interval of 30 seconds, delivered at 90% of the resting motor threshold for both conditions) five days a week (approximately 1 hour each), from their third to seventh visits (total of 5 sessions). Assessment of motor and adaptive function, and plasticity in the motor cortex will be repeated immediately, one week (eighth visit), and four weeks (ninth visit) after the last rTMS session (i.e. 5th session).
The study participants are 15 women with PCOS between the ages of 19-40. All participants must be in good health, non-smokers, and not pregnant or lactating. For three days prior to both study visits, participants follow a standard 2,000 calorie meal plan of approximately 30% fat, 55% carbohydrate and 15% protein. On the morning of the two study visits, participants arrive at the General Clinical Research Center at 0700 h. A venicatheter is inserted into an antecubital vein for collection of blood samples and the catheter is kept open with saline. A baseline blood sample is taken for measurement of estradiol, progesterone, glucose, insulin, testosterone, and sex hormone binding globulin (SHBG). Participants are then served the test meal and asked to consume it within 15 minutes. The high-fat, low-fiber and low-fat, high-fiber meals are isocaloric and are 62% and 6% fat, 24% and 81% carbohydrate, and have 1g and 26.8g of fiber, respectively. After each meal, a blood sample is taken at 30 minutes and every hour for six hours for measurement of testosterone, SHBG, glucose and insulin. During this time participants remain comfortably seated or reclined. After the last blood draw, the catheter was removed and participants are given a complementary meal.